date:Nov 01, 2013
The Bayer Group continued its positive business momentum in the third quarter of 2013, with substantial contributions from the Life Science businesses HealthCare and CropScience.
HealthCare registered encouraging growth, largely due to the outstanding sales performance for our new pharmaceutical products, Bayer Management Board Chairman Dr. Marijn Dekkers explained when the interim report was released on Thursday.
CropScience benefited from a continuing favorable market environment and a goo